Abstract
Immunotherapy (IT) and targeted therapies (TT) have improved survival for many patients (pts) with metastatic non-small cell lung cancer (mNSCLC). However, the lived experience of this cohort of pts is under-studied. We conducted a single centre, qualitative study to understand concerns and supportive care needs of this novel survivor population. (Complementary data was accepted for online only abstract at ASCO 2020)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
